Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)
Stopped Drug manufacturer, Astellas Pharma, informed us that safety and efficacy of Erlotinib and OSI-906 in other oncology studies was determined to be unfavorable.
Conditions
- Recurrent Skin Cancer
- Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
- Squamous Cell Carcinoma of the Skin
- Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity
Interventions
- DRUG: erlotinib hydrochloride
- DRUG: linsitinib
- DRUG: placebo
- RADIATION: radiation therapy
- PROCEDURE: therapeutic conventional surgery
- OTHER: laboratory biomarker analysis
Sponsor
OHSU Knight Cancer Institute
Collaborators